Sanuwave Health Appoints Industry Veteran Dustin Libby as Executive Vice President of Commercial Operations

Rhea-AI Summary

Sanuwave Health (NASDAQ:SNWV) has appointed Dustin Libby as Executive Vice President of Commercial Operations. Libby brings 20 years of medical device industry experience, with a strong track record in commercial growth and sales operations. His notable achievement includes scaling Abiomed's surgical business from $15M to over $500M in revenue as director of commercial operations. Libby's extensive experience includes leadership roles at Smith & Nephew, Arthrex, and Hill-ROM, where he managed sales enablement, operational strategy, KOL development, and product launches. CEO Morgan Frank emphasized Libby's experience in scaling teams and systems as crucial for Sanuwave's growth plans in the wound care market. Libby, who holds a B.S. in Product Design & Development from Keene State College, commenced his role on June 3, 2025.

Positive

• Appointment of experienced executive with 20 years of medical device industry expertise
• Proven track record of scaling businesses, demonstrated by growing Abiomed's surgical division from $15M to $500M in revenue
• Extensive experience in commercial growth, sales operations, and product launches from leadership roles at major medical device companies

Negative

• None.

Libby brings strong team building, growth, and sales operations and systems skills to Sanuwave after a career of growing startups into mid- and large-sized companies.

EDEN PRAIRIE, Minn., June 03, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ:SNWV), a leading provider of next-generation FDA-approved wound care products, is pleased to announce the hiring of Dustin Libby as its EVP of commercial operations.

Libby brings 20 years of medical device experience focused on commercial growth, sales operations, and launch execution.

His career includes leadership roles at Abiomed where, as director of commercial operations, he helped scale a $15M surgical business to over $500M in revenue. Other roles include experience at Smith & Nephew, Arthrex, and Hill-ROM, where he directed sales enablement, operational strategy, KOL development, and product launches across multiple therapeutic areas. This depth of experience positions Dustin to drive scale, agility, and growth at Sanuwave.

Dustin earned his B.S. degree in Product Design & Development at Keene State College

“We are pleased to welcome Dustin to Sanuwave at this exciting time in our growth plans,” said CEO Morgan Frank. “He brings the experience in scaling teams and systems and the ‘run through walls’ energy that will see us through the next evolutions of our plans to extend our leadership in the wound care market.”

“I am thrilled to join Sanuwave and leverage my two decades of medical device experience to drive significant commercial growth. I'm driven to scale our innovative technologies to reach more patients and make a meaningful impact on their lives."

Dustin began work at Sanuwave on June 3, 2025.

About Sanuwave

Sanuwave Health is focused on the research, development, and commercialization of its patented, non-invasive and biological response-activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures.

Sanuwave’s end-to-end wound care portfolio of regenerative medicine products and product candidates help restore the body’s normal healing processes. Sanuwave applies and researches its patented energy transfer technologies in wound healing, orthopedic/spine, aesthetic/cosmetic, and cardiac/endovascular conditions.

Forward-Looking Statements

This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to future financial results, production expectations, plans for future business development activities and expectations regarding the impact of changes in tariff rates. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with regulatory oversight, the Company’s ability to manage its capital resources, competition and the other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.

Contact: investors@sanuwave.com

FAQ

Who is Dustin Libby and what is his new role at Sanuwave Health (SNWV)?

Dustin Libby is a 20-year medical device industry veteran who has been appointed as Executive Vice President of Commercial Operations at Sanuwave Health, starting June 3, 2025.

What are Dustin Libby's major achievements in his previous roles?

As director of commercial operations at Abiomed, Libby helped scale their surgical business from $15M to over $500M in revenue. He also held leadership roles at Smith & Nephew, Arthrex, and Hill-ROM.

What experience does Dustin Libby bring to Sanuwave Health (SNWV)?

Libby brings 20 years of medical device experience focused on commercial growth, sales operations, launch execution, sales enablement, operational strategy, and KOL development across multiple therapeutic areas.

What is Sanuwave Health's (SNWV) business focus?

Sanuwave Health is a leading provider of next-generation FDA-approved wound care products listed on NASDAQ.

What are Sanuwave Health's (SNWV) expectations from Dustin Libby's appointment?

Sanuwave expects Libby to drive scale, agility, and growth, leveraging his experience in scaling teams and systems to extend their leadership in the wound care market.